Rifaximin in patients with portal hypertension due to schistosomiasis in Zambia

Rifaximin in patients with portal hypertension due to schistosomiasis in Zambia: an open-label trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN67590499

Enrollment

Registered

2014-09-30

Start date

2014-01-10

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schistosomiasis, oesophageal varices, portal hypertension Infections and Infestations Schistosomiasis [bilharziasis]

Interventions

One group of 40 Zambian adults with bilharzia of the liver in addition to receiving standard care will receive rifaximin 600 mg orally twice per day for 42 days while the other group will not receive

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Oesophageal varices 2. Schistosomiasis seropositive

Exclusion criteria

Exclusion criteria: 1. HIV seropositive 2. Cirrhosis 3. Hepatitis virus B or C infection

Design outcomes

Primary

Measure	Time frame
Changes in markers of translocation	—

Secondary

Measure	Time frame
1. Changes in markers of fibrosis 2. Changes in inflammatory markers 3. Re-bleeding episodes 4. Death Baseline information will be captured using a questionnaire and blood will be collected for baseline markers of translocation, fibrosis and inflammation. These will be measured using ELISA. Then these patients will be followed up on day 42, day 90 and thereafter for 3 months, making a total of 6 months. At each visit the questionnaire will be administered and blood will be collected for the above assays	—

Measure

Time frame

1. Changes in markers of fibrosis 2. Changes in inflammatory markers 3. Re-bleeding episodes 4. Death Baseline information will be captured using a questionnaire and blood will be collected for baseline markers of translocation, fibrosis and inflammation. These will be measured using ELISA. Then these patients will be followed up on day 42, day 90 and thereafter for 3 months, making a total of 6 months. At each visit the questionnaire will be administered and blood will be collected for the above assays

—

Countries

Zambia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 24, 2026